Needham Reiterates Hold on Sage Therapeutics
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a Hold rating on Sage Therapeutics (NASDAQ:SAGE).
August 01, 2024 | 9:54 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Needham analyst Ami Fadia has reiterated a Hold rating on Sage Therapeutics. This suggests that the analyst does not see significant upside or downside potential in the short term.
The reiteration of a Hold rating by a reputable analyst suggests that the stock is expected to perform in line with the market. This typically indicates a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100